http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 18:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 10, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient ("<strong>API</strong>") supporting the Company's lead oncology program, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html Fri, 10 Jul 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 10, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient ("<strong>API</strong>") supporting the Company's lead oncology program, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html Fri, 10 Jul 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 30, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated June 23, 2026, the initiation of polymer process development and analytical characterization activities being conducted by Nanosoft Polymers ("Nanosoft") in support of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Current activities include polymer synthesis optimization, characterization methodology development, molecular weight assessment, polydispersity evaluation, purification strategy refinement and manufacturing scalability assessments. These efforts are intended to establish a robust and reproducible http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html Tue, 30 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 30, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated June 23, 2026, the initiation of polymer process development and analytical characterization activities being conducted by Nanosoft Polymers ("Nanosoft") in support of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Current activities include polymer synthesis optimization, characterization methodology development, molecular weight assessment, polydispersity evaluation, purification strategy refinement and manufacturing scalability assessments. These efforts are intended to establish a robust and reproducible http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html Tue, 30 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong> W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010, the Company's lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modeling, dose selection and regulatory submissions.</p><p>The studies are being conducted by Nucro-Technics, one of Canada's leading providers of IND-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html Fri, 26 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong> W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010, the Company's lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modeling, dose selection and regulatory submissions.</p><p>The studies are being conducted by Nucro-Technics, one of Canada's leading providers of IND-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html Fri, 26 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Engages+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+ONC010/26680804.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 23, 2026 / </strong>Onco-Innovations Limited (NEO:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a services agreement with Nanosoft Polymers ("Nanosoft"), a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Under the agreement, Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. The work is intended to strengthen the manufacturing and formulation foundation http://www.streetinsider.com/Press+Releases/Onco-Innovations+Engages+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+ONC010/26680804.html Tue, 23 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Engages+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+ONC010/26680804.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 23, 2026 / </strong>Onco-Innovations Limited (NEO:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a services agreement with Nanosoft Polymers ("Nanosoft"), a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Under the agreement, Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. The work is intended to strengthen the manufacturing and formulation foundation http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Engages+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+ONC010/26680804.html Tue, 23 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Reports+Completion+of+300g+Active+Pharmaceutical+Ingredient+for+ONC010+Scale-Up+Supporting+IND-Enabling+Development/26668518.html <p><i><strong>Also Announces Appointment of Mr. Dave Antony as CFO</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 19, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H) </strong>(<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The completed 300g scale-up batch forms part of Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program and follows the successful completion of process development activities and multiple intermediate scale-up campaigns. The program was designed to demonstrate manufacturing reproducibility, http://www.streetinsider.com/Press+Releases/Onco-Innovations+Reports+Completion+of+300g+Active+Pharmaceutical+Ingredient+for+ONC010+Scale-Up+Supporting+IND-Enabling+Development/26668518.html Fri, 19 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Reports+Completion+of+300g+Active+Pharmaceutical+Ingredient+for+ONC010+Scale-Up+Supporting+IND-Enabling+Development/26668518.html <p><i><strong>Also Announces Appointment of Mr. Dave Antony as CFO</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 19, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H) </strong>(<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The completed 300g scale-up batch forms part of Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program and follows the successful completion of process development activities and multiple intermediate scale-up campaigns. The program was designed to demonstrate manufacturing reproducibility, http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Reports+Completion+of+300g+Active+Pharmaceutical+Ingredient+for+ONC010+Scale-Up+Supporting+IND-Enabling+Development/26668518.html Fri, 19 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Project+with+Kuano%2C+Using+Their+Quantum-Based+Platform+to+Deliver+Insights+for+PNKP+Inhibitor+Technology+Optimization/26655497.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 16, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated November 18, 2025, the completion of its pilot project with Kuano Ltd. ("<strong>Kuano</strong>"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.</p><p>Kuano has completed the project and delivered findings derived from molecular modelling and advanced computational analytics that strengthen Onco's understanding of how its PNKP inhibitor and related analogs may interact http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Project+with+Kuano%2C+Using+Their+Quantum-Based+Platform+to+Deliver+Insights+for+PNKP+Inhibitor+Technology+Optimization/26655497.html Tue, 16 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Project+with+Kuano%2C+Using+Their+Quantum-Based+Platform+to+Deliver+Insights+for+PNKP+Inhibitor+Technology+Optimization/26655497.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 16, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated November 18, 2025, the completion of its pilot project with Kuano Ltd. ("<strong>Kuano</strong>"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.</p><p>Kuano has completed the project and delivered findings derived from molecular modelling and advanced computational analytics that strengthen Onco's understanding of how its PNKP inhibitor and related analogs may interact http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Project+with+Kuano%2C+Using+Their+Quantum-Based+Platform+to+Deliver+Insights+for+PNKP+Inhibitor+Technology+Optimization/26655497.html Tue, 16 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Announces+Initiation+of+API+Process+Development+and+Intermediate+Scale-Up+Program+for+its+Proprietary+PNKP+Inhibitor+Technology/26624989.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 9, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce the initiation of process development and intermediate[1] scale-up activities for A83B4C63, the Company's active pharmaceutical ingredient (API) in the Company's proprietary drug candidate, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>"). This milestone marks an important step in advancing the Company's chemistry, manufacturing, and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for First-in-Human clinical evaluation. The program will focus on optimizing synthetic processes, improving yield and reproducibility http://www.streetinsider.com/Press+Releases/Onco-Innovations+Announces+Initiation+of+API+Process+Development+and+Intermediate+Scale-Up+Program+for+its+Proprietary+PNKP+Inhibitor+Technology/26624989.html Tue, 09 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Announces+Initiation+of+API+Process+Development+and+Intermediate+Scale-Up+Program+for+its+Proprietary+PNKP+Inhibitor+Technology/26624989.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 9, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce the initiation of process development and intermediate[1] scale-up activities for A83B4C63, the Company's active pharmaceutical ingredient (API) in the Company's proprietary drug candidate, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>"). This milestone marks an important step in advancing the Company's chemistry, manufacturing, and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for First-in-Human clinical evaluation. The program will focus on optimizing synthetic processes, improving yield and reproducibility http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Announces+Initiation+of+API+Process+Development+and+Intermediate+Scale-Up+Program+for+its+Proprietary+PNKP+Inhibitor+Technology/26624989.html Tue, 09 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Signs+LOI+with+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+the+ONC010+Program/26612439.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 5, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a non-binding Letter of Intent ("<strong>LOI</strong>") with Nanosoft Polymers ("<strong>Nanosoft</strong>"), a biotechnology-focused polymer company, as an initial step toward negotiating a services agreement related to polymer process development, analytical characterization, and drug formulation optimization activities for the Company's exclusively licensed PNKP Inhibitor Technology, ONC010. The LOI is non-binding, and there is no certainty that a services agreement will be entered into.</p><p>Nanosoft specializes in http://www.streetinsider.com/Press+Releases/Onco-Innovations+Signs+LOI+with+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+the+ONC010+Program/26612439.html Fri, 05 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Signs+LOI+with+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+the+ONC010+Program/26612439.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 5, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a non-binding Letter of Intent ("<strong>LOI</strong>") with Nanosoft Polymers ("<strong>Nanosoft</strong>"), a biotechnology-focused polymer company, as an initial step toward negotiating a services agreement related to polymer process development, analytical characterization, and drug formulation optimization activities for the Company's exclusively licensed PNKP Inhibitor Technology, ONC010. The LOI is non-binding, and there is no certainty that a services agreement will be entered into.</p><p>Nanosoft specializes in http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Signs+LOI+with+Nanosoft+Polymers+to+Advance+Polymer+and+Drug+Delivery+Development+for+the+ONC010+Program/26612439.html Fri, 05 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Advances+1kg+Scale-Up+of+B4+Precursor+Supporting+ONC010+Manufacturing+and+Clinical+Development+Program/26593572.html <p><i><strong>Also</strong></i><strong> </strong><i><strong>Announces Marketing Program</strong></i></p> <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 2, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>) (<strong>WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces, further to its news release dated May 19, 2026, the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component supporting the development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) Inhibitor Technology.</p><p>The milestone was achieved through the Company's ongoing chemistry, manufacturing and controls (CMC) collaboration with Dalton Pharma Services and represents an important step in scaling the manufacturing process required to support future http://www.streetinsider.com/Press+Releases/Onco-Innovations+Advances+1kg+Scale-Up+of+B4+Precursor+Supporting+ONC010+Manufacturing+and+Clinical+Development+Program/26593572.html Tue, 02 Jun 2026 18:00:00 -0400 ONNVF